Regulations for Good Clinical Practice Article 4

Clinical trials should be conducted in accordance with the ethical principles of the Declaration of Helsinki.Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks and inconveniences.The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society.The Ethics Committee should safeguard the rights, safety, and well-being of all trial subjects. Special attention should be paid to trials that may include vulnerable subjects.
中文原文 藥品優良臨床試驗作業準則第4條
執行臨床試驗應符合赫爾辛基宣言之倫理原則。
臨床試驗進行前,應權衡對個別受試者及整體社會之可能風險、不便及預期利益。
預期利益應超過可能風險及不便,始得進行試驗。
受試者之權利、安全及福祉為藥品臨床試驗之最重要考量,且應勝於科學及社會之利益。
人體試驗委員會應確保受試者之權利、安全,以及福祉受到保護,且對於易受傷害受試者之臨床試驗,應特別留意。

English translation for reference only; the Chinese text prevails. Not legal advice.